Grant Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	12 Months Ended
	Sep. 01, 2022	Jan. 13, 2022	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities				$ 104,220	$ 489,090
Other current assets				7,600	26,400
National Institutes of Health | Grant Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants				33,400	26,400
Human Immunodeficiency Virus ("HIV") Grant
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant awarded amount. maximum				49,900
Vaccinal Antibody Grant | Grant Revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants				13,300	8,600	$ 8,200
Vaccinal Antibody Grant | Bill & Melinda Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Shares purchased (in shares)		881,365
Shares purchased (in USD per share)		$ 45.38
Shares purchased, aggregate price		$ 40,000
Common stock, shares issued, fair market value		$ 28,500
Closing stock price (in USD per share)		$ 37.65
Underlying shares, premium received		$ 11,300
Transaction price upon exercise				13,100	15,500
Accrued and other liabilities				9,200	$ 7,700
BARDA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential maximum amount of grant	$ 1,000,000
Maximum amount of grant during the base period	$ 55,000
New funding			$ 50,100
Potential future reimbursement				56,500
Total awarded amount				$ 116,300
BARDA | Development of VIR-7229 through Phase 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
New funding			40,000
BARDA | New Monoclonal Antibody Discovery
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
New funding			10,100
BARDA | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional funding			$ 11,200